Reversing Photoaging: The Molecular Impact of Picosecond Laser LIOB

Reversing Photoaging: The Molecular Impact of Picosecond Laser LIOB

Read More
Full Text
2 weeks back

Photoaging presents a complex challenge in clinical dermatology, often requiring aggressive interventions. Traditionally, laser therapies relied on thermal mechanisms that carried significant risks of complications like scarring or dyspigmentation. However, a recent study explores how the 755 nm Alexandrite laser utilizes Laser-Induced Optical Breakdown (LIOB) to treat picosecond laser photoaging. This photomechanical approach avoids excessive heat while triggering profound molecular repair across multiple biological systems.



The Photomechanical Revolution in Skin Rejuvenation


LIOB represents a paradigm shift from conventional photothermolysis. Instead of heating tissue, picosecond pulses create localized plasma-induced micro-vacuoles within the epidermis and dermis. Consequently, these vacuoles initiate a healing response without damaging the surrounding tissue. This process is particularly effective for various skin types, including those prone to post-inflammatory hyperpigmentation. Furthermore, the use of a diffractive lens array concentrates energy into precise micro-spots, ensuring maximum efficacy with minimal clinical downtime.



Reversing picosecond laser photoaging at the Molecular Level


The investigation revealed that consecutive LIOB treatments target multiple biological pathways simultaneously. First, the treatment activates the TGF-β/Smad signaling pathway, which serves as the primary driver of neocollagenesis. In addition, researchers observed a significant decrease in MMP-9 expression. Since MMP-9 degrades the extracellular matrix, its reduction effectively preserves newly synthesized collagen structures. Moreover, the laser treatment restored epidermal barrier function by increasing the expression of filaggrin and aquaporin 3. Notably, the study also recorded a resolution of skin inflammation via reduced NF-κB signaling.



Clinical Outcomes and Histological Evidence


Histological analysis confirmed that these molecular changes translate into visible clinical improvements. For instance, wrinkle scores in experimental groups dropped significantly from 2.11 to 0.78 after three sessions. Researchers also noted normalized epidermal architecture and enhanced collagen density throughout the dermis. Therefore, consecutive LIOB serves as a robust therapeutic intervention that addresses the root causes of UV-induced damage rather than just the surface symptoms.



Frequently Asked Questions


How does LIOB differ from traditional laser therapy?


Traditional lasers rely on thermal damage to stimulate repair, which can lead to prolonged recovery. Conversely, LIOB uses photomechanical force to create micro-vacuoles, stimulating healing with significantly less heat and reduced risk of side effects.


What molecular pathways are affected by picosecond lasers?


The treatment activates the TGF-β/Smad pathway for collagen synthesis and inhibits MMP-9 to prevent matrix degradation. It also enhances barrier proteins like filaggrin and reduces inflammatory markers like NF-κB.


Is this treatment safe for all skin types?


The photomechanical nature of picosecond lasers makes them safer for diverse skin tones, as they minimize the risk of thermal injury and post-inflammatory hyperpigmentation compared to older laser technologies.



Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.



References


Chang CC et al. Picosecond Laser-Induced Optical Breakdown: A Novel Approach to Reversing Photoaging at the Molecular Level. Plast Reconstr Surg. 2026 Mar 17. doi: 10.1097/PRS.0000000000013039. PMID: 41843912.


Huth S et al. Molecular insights into the effects of laser-induced optical breakdown (LIOB) after 1064 nm picosecond laser irradiation using a novel melanocyte-containing 3D skin model. Lasers Med Sci. 2025;40(1):223. doi: 10.1007/s10103-025-04474-z.


Gorski J et al. Dexpanthenol in wound healing after medical and cosmetic interventions. Pharmaceuticals (Basel). 2020;13(7):138. doi: 10.3390/ph13070138.

Login to continue

More from MedShots Daily

Reversing Photoaging: The Molecular Impact of Picosecond Laser LIOB
Reversing Photoaging: The Molecular Impact of Picosecond Laser LIOB

A study highlights how picosecond laser treatments reverse UV-induced skin damage through molecular pathways like TGF-β and MMP-9 reduction....

2 weeks back

Read More
Full Text
Macrophage Metabolic Reprogramming in Sepsis: New Insights for Targeted Therapy
Macrophage Metabolic Reprogramming in Sepsis: New Insights for Targeted Therapy

A review of macrophage metabolic reprogramming in sepsis, highlighting key signaling pathways like HIF-1α and potential immunometabolic therapeutic targets....

Today

Read More
Full Text
Predicting Spontaneous Labor Onset at Term: The PREDICT Study Insights
Predicting Spontaneous Labor Onset at Term: The PREDICT Study Insights

The PREDICT study provides a model to estimate spontaneous labor probability between 39-41 weeks, aiding shared decision-making in term pregnancies....

Today

Read More
Full Text
Expression of Concern Issued for Cardiomyocyte Study Over Research Integrity Issues
Expression of Concern Issued for Cardiomyocyte Study Over Research Integrity Issues

The International Journal of Molecular Medicine has issued an Expression of Concern for a 2012 study on HSP90 and cardiomyocytes due to image integrity issu...

Today

Read More
Full Text
Novel cfDNA Scavenger Breakthrough for Neural Repair in Spinal Cord Injury
Novel cfDNA Scavenger Breakthrough for Neural Repair in Spinal Cord Injury

Scientists design a cfDNA scavenger that neutralizes inflammation and promotes neural repair after spinal cord injury by leveraging extracellular vesicles....

Today

Read More
Full Text
Astragaloside IV: A Potential Targeted Therapy for Pituitary Tumors?
Astragaloside IV: A Potential Targeted Therapy for Pituitary Tumors?

A study identifies Astragaloside IV as a potential pituitary tumor treatment by targeting TUBB4B and the STMN1/ERK pathway to inhibit cell growth....

Today

Read More
Full Text
Showing Page 1 of 1(5 items total)
Go to Page

"Wherever the art of Medicine is loved, there is also a love of Humanity."

— Hippocrates

made with❤️byOmnicuris